Table 1 Clinical characteristics of 129 EOC patients.
Variables | Training group | Validated group | p-value |
|---|---|---|---|
Number | 91 | 38 | |
Age (years), n (%) | 0.39 | ||
< 60 | 57 (62.6%) | 20 (52.6%) | |
≥ 60 | 34 (37.4%) | 18 (47.4%) | |
CD8+ count, mean ± SD | 196.77 ± 314.81 | 158.05 ± 213.24 | 0.81 |
CD39+count, mean ± SD | 1639.32 ± 1355.22 | 1604.58 ± 1939.45 | 0.37 |
CD39+CD8+T cells count, mean ± SD, % | 84.02 ± 162.49 | 68.08 ± 130.53 | 0.70 |
CD8+ in CK+ region, mean ± SD | 84.77 ± 194.63 | 93.76 ± 180.23 | 0.82 |
CD8+ in CK− region, mean ± SD | 112 ± 209.17 | 64.29 ± 88.44 | 0.39 |
CD39+ in CK+ region, mean ± SD, % | 20.16 ± 25.17 | 26.38 ± 29.76 | 0.45 |
CD39+ in CK − region, mean ± SD | 1619.16 ± 1343.22 | 1578.2 ± 1931.63 | 0.35 |
CD39+CD8+T cells in CK+ region, mean ± SD, % | 32.02 ± 84.91 | 39.24 ± 106.82 | 0.82 |
CD39+CD8+ T cells in CK− region, mean ± SD, % | 52 ± 111.57 | 28.84 ± 57.8 | 0.49 |
FIGO stage | 1.00 | ||
III | 84 (92.3%) | 35 (92.1%) | |
IV | 7 (7.7%) | 3 (7.9%) | |
Pathology | 0.65 | ||
HGSOC | 61 (67%) | 27 (71.1%) | |
Endometrioid | 23 (25.3%) | 10 (26.3%) | |
Others | 7 (7.7%) | 1 (2.6%) | |
Tumor residual size | 0.38 | ||
0 cm | 35 (38.5%) | 18 (47.4%) | |
≥ 1 cm | 41 (45.1%) | 17 (44.7%) | |
> 1 cm | 15 (16.5%) | 3 (7.9%) | |
Platinum-based regimen | 0.84 | ||
TC | 65 (71.4%) | 25 (65.8%) | |
TP | 21 (23.1%) | 11 (28.9%) | |
Other | 5 (5.5%) | 2 (5.3%) | |
PFI | 0.90 | ||
< 6 moths | 8 (8.8%) | 3 (7.9%) | |
6–12 moths | 21 (23.1%) | 7 (18.4%) | |
≥ 12 moths | 62 (68.1%) | 28 (73.7%) |
